Publication date: Dec 17, 2024
After the end of the COVID-19 public health emergency, we analysed the relationship between Systemic Lupus Erythematosous (SLE) and COVID-19 from the virologist’s perspective based on recent findings. SLE and COVID-19 co-morbidity present unique challenges, as individuals with SLE may be at increased risk for severe COVID-19 illness due to immune system abnormalities and ongoing therapies. Effective management of both diseases requires careful monitoring, adherence to vaccination programs, preventive measures and approved and patient-tailored therapies. This review covers various aspects, including the clinical outcome of SLE patients infected by SARS-CoV-2, the impact of this infection on SLE onset or flare-ups and the benefits of vaccination for this population. Furthermore, this review presents the most recent recommendations on clinical management of COVID-19 in rheumatic patients, including those with SLE, discussing the currently available therapeutic options. Finally, we explore the most effective tools for SARS-CoV-2 diagnosis in autoimmune conditions and examine prognostic biomarkers in COVID-19 rheumatic patients with potential implications on their clinical oversight. By adopting a comprehensive approach, we address these complexities from the virologist’s perspective, aiming to improve health care for this vulnerable population.
Concepts | Keywords |
---|---|
Biomarkers | biomarkers |
Covid | COVID-19 drug treatment |
Severe | COVID-19 testing |
Vaccination | COVID-19 vaccines |
SARS-cov-2 | |
Systemic lupus erythematosus |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 |
disease | MESH | emergency |
disease | MESH | morbidity |
pathway | REACTOME | Immune System |
disease | MESH | abnormalities |
disease | MESH | infection |
disease | MESH | Long Covid |
disease | MESH | Systemic lupus erythematosus |
pathway | KEGG | Systemic lupus erythematosus |